首页> 外文期刊>The Lancet >Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.
【24h】

Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.

机译:直肠癌患者的术前放疗与选择性术后放化疗(MRC CR07和NCIC-CTG C​​016):一项多中心,随机试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Preoperative or postoperative radiotherapy reduces the risk of local recurrence in patients with operable rectal cancer. However, improvements in surgery and histopathological assessment mean that the role of radiotherapy needs to be reassessed. We compared short-course preoperative radiotherapy versus initial surgery with selective postoperative chemoradiotherapy. METHODS: We undertook a randomised trial in 80 centres in four countries. 1350 patients with operable adenocarcinoma of the rectum were randomly assigned, by a minimisation procedure, to short-course preoperative radiotherapy (25 Gy in five fractions; n=674) or to initial surgery with selective postoperative chemoradiotherapy (45 Gy in 25 fractions with concurrent 5-fluorouracil) restricted to patients with involvement of the circumferential resection margin (n=676). The primary outcome measure was local recurrence. Analysis was by intention to treat. This study is registered, number ISRCTN 28785842. FINDINGS: At the time of analysis, which included all participants, 330 patients had died (157 preoperative radiotherapy group vs 173 selective postoperative chemoradiotherapy), and median follow-up of surviving patients was 4 years. 99 patients had developed local recurrence (27 preoperative radiotherapy vs 72 selective postoperative chemoradiotherapy). We noted a reduction of 61% in the relative risk of local recurrence for patients receiving preoperative radiotherapy (hazard ratio [HR] 0.39, 95% CI 0.27-0.58, p<0.0001), and an absolute difference at 3 years of 6.2% (95% CI 5.3-7.1) (4.4% preoperative radiotherapy vs 10.6% selective postoperative chemoradiotherapy). We recorded a relative improvement in disease-free survival of 24% for patients receiving preoperative radiotherapy (HR 0.76, 95% CI 0.62-0.94, p=0.013), and an absolute difference at 3 years of 6.0% (95% CI 5.3-6.8) (77.5%vs 71.5%). Overall survival did not differ between the groups (HR 0.91, 95% CI 0.73-1.13, p=0.40). INTERPRETATION: Taken with results from other randomised trials, our findings provide convincing and consistent evidence that short-course preoperative radiotherapy is an effective treatment for patients with operable rectal cancer.
机译:背景:术前或术后放疗可降低可手术直肠癌患者局部复发的风险。然而,手术和组织病理学评估的改善意味着放疗的作用需要重新评估。我们将短程术前放疗与初次手术与选择性术后放化疗相比较。方法:我们在四个国家的80个中心进行了一项随机试验。通过最小化程序,将1350例可手术的直肠腺癌患者随机分配至短期疗程术前放疗(五分之25 Gy; n = 674)或接受选择性放化疗后的初次手术(25分之45 Gy,同时进行) 5-氟尿嘧啶)仅限于累及环周切缘的患者(n = 676)。主要结局指标是局部复发。分析是按意向进行的。该研究已注册,编号ISRCTN28785842。结果:在分析时(包括所有参与者),有330例患者死亡(157例术前放疗组vs 173例选择性术后放化疗患者),并且存活患者的中位随访时间为4年。 99例患者发生了局部复发(术前放疗27例,术后选择性放化疗72例)。我们注意到术前放疗患者局部复发的相对风险降低了61%(危险比[HR] 0.39,95%CI 0.27-0.58,p <0.0001),并且3年绝对差异为6.2%( 95%CI 5.3-7.1)(4.4%术前放疗vs 10.6%选择性术后放化疗)。我们记录了接受术前放疗的患者的无病生存期相对改善了24%(HR 0.76,95%CI 0.62-0.94,p = 0.013),3年绝对差异为6.0%(95%CI 5.3- 6.8)(77.5%vs 71.5%)。两组之间的总生存期无差异(HR 0.91,95%CI 0.73-1.13,p = 0.40)。解释:结合其他随机试验的结果,我们的发现提供了令人信服和一致的证据,表明术前短程放疗是可手术直肠癌患者的有效治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号